New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
10:16 EDTRIMM, RDS.A, MYGN, SJM, CNK, INFY, EIX, QLGC, KNXA, HMA, CF, DVA, TEVA, OXY, JNS, ELX, RATEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Hold from Buy at Canaccord... Bankrate (RATE) downgraded to Sector Perform from Outperform at RBC Capital... CF Industries (CF) downgraded to Neutral from Overweight at Piper Jaffray... Cinemark (CNK) downgraded to Neutral from Overweight at JPMorgan... Emulex (ELX) downgraded to Sell from Neutral at Goldman... Health Management (HMA) downgraded to Sell from Fair Value at CRT Capital... J.M. Smucker (SJM) downgraded to Equal Weight from Overweight at Stephens... Janus Capital (JNS) downgraded to Sell from Neutral at Goldman... Kenexa (KNXA) downgraded to Market Perform from Outperform at JMP Securities... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Mizuho... Occidental Petroleum (OXY) downgraded to Hold from Buy at Deutsche Bank... QLogic (QLGC) downgraded to Sell from Neutral at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Overweight at JPMorgan... Royal Dutch Shell (RDS.A) downgraded to Hold from Buy at Deutsche Bank... Teva (TEVA) downgraded to Neutral from Buy at UBS... Edison International (EIX) downgraded to Market Perform from Outperform at Bernstein... Research in Motion (RIMM) downgraded to Sell from Hold at Canaccord... DreamWorks (DWA) downgraded to Sell from Hold at Stifel Nicolaus... Infosys (INFY) downgraded to Neutral from Outperform at Cowen.
News For A;TEVA;EIX;RIMM;DVA;INFY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 27, 2015
12:10 EDTTEVATeva to sweeten offer for Mylan before July shareholder vote, NY Post says
Subscribe for More Information
08:24 EDTTEVAFDA reports paragraph IV patent challenge received for Treanda
Subscribe for More Information
May 26, 2015
07:19 EDTDVALeerink to hold a tour
Subscribe for More Information
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 19, 2015
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 17, 2015
15:07 EDTINFYInfosys likely to spend cash on acquisitions rather than returns, Barron's says
Infosys is likely to spend its capital on additional acquisitions rather than shareholder returns, Barron's contends in its 'International Trader - Asia' column. Barron's notes that the company has targeted an 18% annualized rate of revenue growth and looks to deepen its presence in social, mobile, "big data," and cloud through buyouts. Reference Link
May 15, 2015
17:08 EDTTEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
12:39 EDTEIXWells identifies NextEra, Sempra as among favorite utility names
Utilities as a group have dropped in recent months and there are several names in the sector that offer relative value and exposure to secular growth trends, Wells Fargo stated in a note to investors today. WHAT'S NEW: The utilities sector is trading at a forward multiple that is 93% of the S&P 500, versus the ten year average of 102%, according to Wells. Moreover, utilities are "slightly cheap" relative to interest rates, the firm thinks. NextEra Energy (NEE) and Sempra Energy (SRE) have the best growth opportunities in the utility space, according to Wells. They also have proven management teams and are well-positioned to exploit long-term trends, including renewable energy and energy infrastructure, the firm believes. ITC Holdings (ITC) has reached an attractive entry point and, to a degree, offers a near-term hedge against an interest rate increase, according to the firm. Edison International (EIX) and Xcel Energy (XEL) are underappreciated regulated utilities, added Wells. Edison trades in-line with its peers despite superior EPS growth potential and Xcel trades at a 3%-6% discount to the sector despite its at least in-line EPS growth and comparable regulatory risk, which might ease, the firm added. PRICE ACTION: In early afternoon trading, NextEra rose 0.5%, Sempra gained 0.6%, Edison added 0.6%, Xcel climbed 0.4% and ITC was little changed.
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
07:49 EDTEIXWells Fargo identifies favorite utility names
Wells Fargo says that NextEra Energy (NEE) and Sempra Energy (SRE) have the best growth opportunities in the utility space as well as proven management teams, and are well-positioned to exploit long-term trends. ITC Holdings (ITC) has reached an attractive entry point, and, to a degree, offers a near-term hedge against an interest rate increase, according to the firm. Edison International (EIX) and Xcel Energy (XEL) are underappreciated regulated utilities, added Wells.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use